

Attorney Docket No.: **RTS-0348**
Inventors: **Bennett and Freier**
Serial No.: **10/003,354**
Filing Date: **December 6, 2001**
Page 3

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

C1
Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to nucleobases 83 through 355 of a 5'-untranslated region, nucleobases 458 through 2045 of a coding region, nucleobases 2050 through 2069 of a stop codon region, or nucleobases 2063 through 3659 of a 3'-untranslated region of a nucleic acid molecule encoding phosphatidylinositol-4-phosphate 5-kinase, I α (SEQ ID NO: 3), wherein said compound specifically hybridizes with ~~said nucleic acid molecule encoding phosphatidylinositol-4-phosphate 5-kinase, I α~~ one of said regions and inhibits the expression of phosphatidylinositol-4-phosphate 5-kinase, I α .

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (previously canceled)

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Attorney Docket No.: **RTS-0348**
Inventors: **Bennett and Freier**
Serial No.: **10/003,354**
Filing Date: **December 6, 2001**
Page 4

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled)

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Attorney Docket No.: RTS-0348
Inventors: Bennett and Freier
Serial No.: 10/003,354
Filing Date: December 6, 2001
Page 5

C1
Claim 15 (previously amended): A method of inhibiting the expression of phosphatidylinositol-4-phosphate 5-kinase, $I\alpha$ in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of phosphatidylinositol-4-phosphate 5-kinase, $I\alpha$ is inhibited.

Claims 16-18 (previously canceled)

Claims 19-20 (canceled)
